Product Description
TLR9 Agonist for Myeloid Malignancies and Lymphoid Malignancies (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02452697)
Mechanisms of Action: TLR9 Agonist
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cristina Gasparetto
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Nut Hypersensitivity|Environmental Hypersensitivity|Bone Marrow Transplantation|Allogeneic Stem Cell Transplant|Liver Transplant|Graft vs Host Disease|Hematopoietic Stem Cell Transplant|Animal Hypersensitivity|Pregnancy Outcomes|Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Pro00042574 | P2 |
Withdrawn |
Lymphoma, Non-Hodgkin |
2020-01-01 |
|
| NK-DCI | P2 |
Active, not recruiting |
Liver Transplant|Hematopoietic Stem Cell Transplant|Pregnancy Outcomes|Animal Hypersensitivity|Allogeneic Stem Cell Transplant|Graft vs Host Disease|Environmental Hypersensitivity|Nut Hypersensitivity|Bone Marrow Transplantation |
2022-07-23 |
50% |